

DAFTAR PUSTAKA

1. Michael Ng A, Baradhi KM. Benign Prostatic Hyperplasia Continuing Education Activity [Internet]. NCBI Bookshelf. 2022 [cited 2022 Jul 25]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK558920/>
2. Yeboah ED. PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER IN AFRICANS AND AFRICANS IN THE DIASPORA. *J West Afr Coll Surg.* 2016;6(4):1–30.
3. Xu XF, Liu GX, Guo YS, Zhu HY, He DL, Qiao XM, et al. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. *Am J Mens Health.* 2021;15(4).
4. Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. *Sci Rep.* 2017 Dec 1;7(1).
5. Mulyadi HTS, Sugiarto. Prevalensi Hiperplasia Prostat dan Adenokarsinoma Prostat secara Histopatologi di Laboratorium Patologi Anatomi Rumah Sakit Umum Daerah Cibinong. *Muhammadiyah Journal of Geriatric.* 2020;1(1).
6. Lestari LL. Hubungan usia dan pekerjaan dengan kejadian BPH di Poli Bedah dan ruang rawat inap bedah pria RSUD Achmad Mochtar Bukittinggi tahun 2014. [Bukittinggi]: Sekolah Tinggi Ilmu Kesehatan Perintis; 2014.
7. Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Vol. 65, *Gerontology.* S. Karger AG; 2019. p. 458–64.

8. Tamsulosin. In: Meyler's Side Effects of Drugs. Elsevier; 2016. p. 702–5.
9. Van der Worp H, Kollen BJ, Vermist T, Steffens MG, Blanker MH. Symptom improvement and predictors associated with improvement after 6 weeks of alpha-blocker therapy: An exploratory, single-arm, open-label cohort study. *PLoS One*. 2019 Jul 1;14(7).
10. Tjahjodjati, Soebadi DM, Umbas R, et al. Panduan Pentalaksanaan Klinis Pembesaran Prostat Jinak. Bandung: Ikatan Ahli Urologi Indonesia; 2021.
11. Hamid SHI, Mohamedahmed AY, Sharfi AR. Correlation between the Size of the Prostate, Post Void Residual Volume, PSA Level and IPSS in Men with LUTS in Three Major Urology Centers in Khartoum. *International Journal of Surgical Research [Internet]*. 2020;9(1):1–8. Available from: <https://www.researchgate.net/publication/339461161>
12. Mamoulakis C, Oelke M. Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives. In: *Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside*. Elsevier; 2018. p. 113–33.
13. Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. *Int J Impot Res*. 2008;19–26.
14. Hanai T, Matsumoto S, Shouji S, Usui Y, Tang XY, Kato Y, et al. Changes in PSA due to administration of α 1-adrenergic receptor blockers in patients with mildly elevated prostate-specific antigen (PSA): comparison between

benign prostatic hyperplasia/lower urinary tract disease and prostate cancer. *Bulletin of Urology*. 2009;55:187–91.

15. Demir M, Akin Y, Terim KAK, Gulum M, Buyukfirat E, Ciftci H, et al. Evaluation of apoptosis indexes in currently used oral alphablockers in prostate: A pilot study. *International Braz J Urol*. 2018 May 1;44(3):600–7.
16. Tahmatzopoulos A, Kyprianou N. Apoptotic Impact of α 1-Blockers on Prostate Cancer Growth: A Myth or an Inviting Reality? *Prostate*. 2004 Apr 1;59(1):91–100.
17. Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, et al. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia. Vol. 17, *International Journal of Molecular Sciences*. MDPI AG; 2016.
18. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? Vol. 127, *BJU International*. John Wiley and Sons Inc; 2021. p. 389–99.
19. Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Vol. 12, *Therapeutic Advances in Urology*. SAGE Publications Inc.; 2020.
20. Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. *BJU Int*. 2021 Jun 1;127(6):722–8.

21. Singh O, Bolla SR. Anatomy, Abdomen and Pelvis, Prostate [Internet]. NCBI Bookshelf. 2021 [cited 2022 Sep 15]. Available from: <https://pubmed.ncbi.nlm.nih.gov/31082031/>
22. Aaron LT, Franco OE, Hayward SW. Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia. *Urologic Clinics of North America*. 2016 Aug 1;43(3):279–88.
23. Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and Benign Prostatic Hyperplasia. Vol. 7, *Sexual Medicine Reviews*. Elsevier B.V.; 2019. p. 259–71.
24. Lepor H. Pathophysiology of Benign Prostatic Hyperplasia in the Aging Male Population. *Rev Urol*. 2005;7(suppl 4):S3–12.
25. Reza HS, Ali Z, Tara H, Ali B. Age-specific reference ranges of prostate-specific antigen in the elderly of Amirkola: A population-based study. *Asian J Urol*. 2021 Apr 1;8(2):183–8.
26. Roehrborn CG. ILC IN THE TREATMENT OF BPH Benign Prostatic Hyperplasia: An Overview. 2005.
27. Foo KT. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? Vol. 37, *World Journal of Urology*. Springer Verlag; 2019. p. 1293–6.
28. Baron M, Cornu JN. Medical Aspects of the Treatment of LUTS/BPH: Alpha-Blockers. In: *Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to Bedside*. Elsevier; 2018. p. 177–88.

29. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Vol. 8, Translational Andrology and Urology. AME Publishing Company; 2019. p. 529–39.
30. Moon HW, Yang JH, Choi JB, Bae WJ, Cho HJ, Hong SH, et al. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia. *Sci Rep*. 2018 Dec 1;8(1).
31. Nachawati D, Patel JB. Alpha Blockers [Internet]. NCBI Bookshelf. 2022 [cited 2022 Sep 1]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK556066/>
32. David MK, Leslie SW. Prostate Specific Antigen. NCBI Bookshelf. 2022.
33. Park DS, Oh JJ, Hong JY, Hong YK, Choi DK, Gong IH, et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: A large-scale Korean screening study. *Asian J Androl*. 2013 Mar;15(2):249–53.
34. Paick JS, Min CC, Sang HS, Soo WK, Ja HK. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. *J Korean Med Sci*. 2008 Jun;23(3):509–13.
35. Chłosta P, Drewa T, Kaplan S. α -blockade, apoptosis, and prostate shrinkage: How are they related? Vol. 66, *Central European Journal of Urology*. Polish Urological Association; 2013. p. 189–94.

36. Prasetyo ZA, Budaya TN, Daryanto B. Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Undergoing Transurethral Resection of the Prostate (TURP). *Jurnal Kedokteran Brawijaya*. 2021 Aug 31;31(4):4.
37. Baradhi NM. *Benign Prostatic Hyperplasia*. Statpearls Publishing. 2022.
38. Lim K bin. Epidemiology of clinical benign prostatic hyperplasia. Vol. 4, *Asian Journal of Urology*. Editorial Office of Asian Journal of Urology; 2017. p. 148–51.
39. Liu TT, Thomas S, Mclean DT, Roldan-Alzate A, Hernando D, Ricke EA, et al. Prostate enlargement and altered urinary function are part of the aging process. *Aging*. 2019;11(9):2653–60.
40. Sarauw A, Nompo R, Arvia A. Pengaruh pendidikan kesehatan tentang penyakit Benigna Prostate Hyperplasia (BPH) terhadap pengetahuan pasien di Ruang Bedah Pria RSUD Jayapura. *Sentani Nursing Journal*. 2021 Apr 15;3(1):1–7.
41. Maharany RA. Hubungan pekerjaan dengan kejadian Benigna Prostat Hiperplasia (BPH) di Rumah Sakit Pertamina Bintang Amin Bandar Lampung tahun 2020-2021 [Skripsi]. [Lampung]: Universitas Malahayati; 2022.
42. Samudera IMA, Nandana PI. Gambaran karakteristik, International Prostate Symptom Score, dan Quality of Life pasien Benign Prostate Hyperplasia di RSUD Kota Mataram. *Jurnal Kedokteran*. 2020;9(4):323–7.

43. Ramadhanurrosita N, Soebhali B, Nugroho H. The correlation of International Prostate Symptom Score (IPSS) with Qmax on uroflowmetry of Benign Prostatic Hyperplasia (BPH) patients at Abdul Wahab Sjahranie Hospital in Samarinda. *JURNAL ILMU KESEHATAN*. 2019;7(2).
44. Tubaro A, de Nunzio C, Mariani S, Trucchi A, Miano R, Vicentini C, et al. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. *Urology*. 2010 Aug;76(2):436–41.
45. Kyprianou N, Jacobs SC. Induction of Apoptosis in the Prostate by 1-Adrenoceptor Antagonists: A Novel Effect of “Old” Drugs. *Curr Urol Rep*. 2000;1:89–96.
46. Server Pastor G, Nicolás Torralba JA, Bañón Pérez V, Valdevira Nadal P, Rigabert Montiel M, López Cubillana P, et al. Is PSA density able to predict the response to alpha-blockers in benign prostatic hyperplasia? *Actas Urol Esp*. 2001;25(2):115–8.
47. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. Vol. 169, *Journal of Urology*. Lippincott Williams and Wilkins; 2003. p. 1520–5.
48. Sun L, Sun C, Zhou S, Zhang L, Hu W. Tamsulosin attenuates high glucose-induced injury in glomerular endothelial cells. *Bioengineered*. 2021;12(1):5184–94.